Income Tax Expense (Benefit) in USD of VYNE Therapeutics Inc. from 2017 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
VYNE Therapeutics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2017 to Q2 2025.
  • VYNE Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2025 was $0.000.
  • VYNE Therapeutics Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2025 was $4K.
  • VYNE Therapeutics Inc. annual Income Tax Expense (Benefit) for 2024 was $4K.
  • VYNE Therapeutics Inc. annual Income Tax Expense (Benefit) for 2023 was $0.000, a 100% decline from 2022.
  • VYNE Therapeutics Inc. annual Income Tax Expense (Benefit) for 2022 was $13K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

VYNE Therapeutics Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 $4K $0 $0 Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $4K $0 $0 Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $4K $4K +$4K Oct 1, 2024 Dec 31, 2024 10-K 2025-03-06
Q3 2024 $0 $0 $0 Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $0 $0 $0 Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 $0 $0 $0 Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $0 $0 -$13K -100% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-06
Q3 2023 $13K $0 $0 Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $13K $0 $0 Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $13K $0 $0 Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $13K $13K +$461K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$448K $0 $0 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$448K $0 $0 Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$448K $0 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$448K -$448K -$448K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 $0 $0 -$1K -100% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $1K $0 +$259K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$258K $0 $0 Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$258K $0 $0 Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$258K $1K +$1K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$259K -$259K -$259K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $0 $0 +$176K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$176K $0 Oct 1, 2019 Dec 31, 2019 10-K 2021-03-04
Q3 2019 $0 Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $0 Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$176K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11

VYNE Therapeutics Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $4K +$4K Jan 1, 2024 Dec 31, 2024 10-K 2025-03-06
2023 $0 -$13K -100% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-06
2022 $13K +$461K Jan 1, 2022 Dec 31, 2022 10-K 2024-03-01
2021 -$448K -$190K -73.6% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-14
2020 -$258K -$82K -46.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$176K -$388K -183% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-04
2018 $212K +$212K Jan 1, 2018 Dec 31, 2018 10-K 2021-03-04
2017 $0 Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.